Bridge program keeps seizure drug available for eligible patients
NCT ID NCT02307578
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This program provides continued access to the seizure medication perampanel (Fycompa) for people who completed certain earlier studies and are still benefiting from the drug. It runs until the drug is commercially available in their country or no participants remain. Only those already in the program or specific prior studies are eligible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Perampanel (also known as Fycompa)
What this could lead to
If successful, this program ensures continued access to perampanel for people with certain seizure disorders until the drug is commercially available in their country.
What could go wrong
This is an access program, not a new trial, so it does not test new benefits or risks. Participants must have already shown a positive response to perampanel in prior studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY GENERALIZED TONIC-CLONIC SEIZURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Artroscan
Ostrava-Trebovice, Czechia
-
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktató Kórház
Miskolc, Hungary
-
Centre Neurologique William Lennox
Ottignies, Belgium
-
Childrens University Hospital
Riga, Latvia
-
Clinical Centre of Serbia
Belgrade, Serbia
-
Cliniques Universitaires Saint-Luc
Brussels, Belgium
-
Dél-Pesti Centrumkórház Országos Hematológiai és Infektológiai Intézet
Budapest, Hungary
-
Hospital Clinico San Carlos
Madrid, Spain
-
Hospital Padre Hurtado
Santiago, Chile
-
Hospital Sant Joan de Deu
Esplugues de Llobregat, Spain
-
Hospital Universitario Virgen del Rocio -
Seville, Spain
-
Hôpital Universitaire des Enfants Reine Fabiola
Brussels, Belgium
-
Instytut Psychiatrii Neurologii
Warsaw, Poland
-
Klaipeda University Hospital
Klaipėda, Lithuania
-
Magyarorszagi Reformatus Egyhaz (MRE) Bethesda Gyermekkorhaza
Budapest, Hungary
-
NZOZ Centrum Neurologii Dzieciecej i Leczenia Padaczki
Kielce, Poland
-
Nzoz Novo-Med
Katowice, Poland
-
Országos Idegsebészeti Tudományos Intézet
Budapest, Hungary
-
Oy Neurodiagnostika Ap
Tallinn, Estonia
-
Pécsi Tudományegyetem
Pécs, Hungary
-
Rajna és Fiai Kereskedelmi és Szolgáltató Kft.
Budapest, Hungary
-
Riga 1st Hospital
Riga, Latvia
-
Servus Salvus Egeszsegugyi Szolgaltato Kft.
Budapest, Hungary
-
Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
Poznan, Poland
-
Tartu University Hospital
Tartu, Estonia
-
Uniwersyteckie Centrum Kliniczne - PPDS
Gdansk, Poland
-
Všeobecná fakultní nemocnice, Pragtis s.r.o
Prague, Czechia